(Albany, USA) DelveInsight’s “Leber’s Hereditary Optic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Leber’s Hereditary Optic Neuropathy, historical and forecasted epidemiology as well as the Leber’s Hereditary Optic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Leber’s Hereditary Optic Neuropathy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Leber’s Hereditary Optic Neuropathy market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Leber’s Hereditary Optic Neuropathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Leber’s Hereditary Optic Neuropathy market.
Request for a Free Sample Report @ Leber’s Hereditary Optic Neuropathy Market Forecast
Some facts of the Leber’s Hereditary Optic Neuropathy Market Report are:
- According to DelveInsight, Leber’s Hereditary Optic Neuropathy market size is expected to grow at a decent CAGR by 2032.
- Leading Leber’s Hereditary Optic Neuropathy companies working in the market are GenSight, Stealth Biotherapeutics, and others.
- Key Leber’s Hereditary Optic Neuropathy Therapies expected to launch in the market are GS010, Elamipretide, and others.
- Current major Leber’s Hereditary Optic Neuropathy treatment options are Raxone (idebenone), α-2 agonist (Brimonidine), Steroids and immunosuppressants, and others.
- As per Man et. al. (2016), LHON is characterized by a marked gender bias, with males more likely to become affected than females.
- Some late stage products are under development to cater the unmet needs in Leber’s Hereditary Optic Neuropathy (LHON) treatment scenario. Among them, GS010 by GenSight anticipates commercial launch, follow approval by the end of 2023, according to the company.
Leber’s Hereditary Optic Neuropathy Overview
Leber’s hereditary optic neuropathy (LHON) is a specific type of “inherited optic atrophies” or “hereditary optic neuropathies.” It refers to a dysfunction of the optic nerve caused by specific genetic mutations in mitochondrial DNA. Unlike typical Mendelian inheritance patterns, LHON is transmitted in a non-Mendelian manner.
LHON is characterized by the painless, gradual loss of central vision during early adulthood, affecting both eyes. Typically, symptoms begin in one eye first, followed by visual impairment in the other eye a few weeks later. In rare cases, individuals may experience additional neurological abnormalities like peripheral neuropathy, postural tremor, nonspecific myopathy, or movement disorders. LHON is caused by mutations in mitochondrial DNA and is strictly inherited through maternal lines.
Diagnosis of LHON is primarily based on ophthalmologic findings, including specialized visual tests. These tests involve a thorough examination of the dilated fundus to identify specific changes in the optic disc and vascular alterations during the acute phase. Other diagnostic measures include visual field testing, electrophysiological studies, imaging (particularly OCT), and molecular genetic testing to confirm LHON by detecting mutations in mitochondrial genes associated with the condition.
Supportive management and treatment options for affected individuals include the use of visual aids, occupational rehabilitation, and local social services. It is important for individuals with LHON to avoid smoking and excessive alcohol consumption, as these activities generate reactive oxygen species (ROS), which can further impair mitochondrial function.
Learn more about Leber’s Hereditary Optic Neuropathy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Leber’s Hereditary Optic Neuropathy Market
The Leber’s Hereditary Optic Neuropathy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Leber’s Hereditary Optic Neuropathy market trends by analyzing the impact of current Leber’s Hereditary Optic Neuropathy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Leber’s Hereditary Optic Neuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Leber’s Hereditary Optic Neuropathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Leber’s Hereditary Optic Neuropathy market in 7MM is expected to witness a major change in the study period 2019-2032.
Currently, Raxone (idebenone) is the only available medicinal product authorized to treat LHON within the European Union. However, there are many promising novel treatment modalities that are currently being evaluated, with several clinical trials underway or in the planning stages. Supportive measures and genetic counseling remain of great importance for these patients. Currently the most exciting potential means of treating LHON are within the field of gene therapy. LHON’s unique characteristics as a mitochondrial disease that primarily affects the eye, with sequential involvement of the second eye, provides a “window of opportunity” for treatment and makes the disorder particularly suitable as an in vivo “laboratory.”
Leber’s Hereditary Optic Neuropathy Epidemiology
The Leber’s Hereditary Optic Neuropathy epidemiology section provides insights into the historical and current Leber’s Hereditary Optic Neuropathy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Leber’s Hereditary Optic Neuropathy market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Leber’s Hereditary Optic Neuropathy Epidemiology @ Leber’s Hereditary Optic Neuropathy Market Dynamics
Leber’s Hereditary Optic Neuropathy Drugs Uptake
This section focuses on the uptake rate of the potential Leber’s Hereditary Optic Neuropathy drugs recently launched in the Leber’s Hereditary Optic Neuropathy market or expected to be launched in 2019-2032. The analysis covers the Leber’s Hereditary Optic Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Leber’s Hereditary Optic Neuropathy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Leber’s Hereditary Optic Neuropathy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Leber’s Hereditary Optic Neuropathy Pipeline Development Activities
The Leber’s Hereditary Optic Neuropathy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Leber’s Hereditary Optic Neuropathy key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Leber’s Hereditary Optic Neuropathy pipeline development activities @ https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Leber’s Hereditary Optic Neuropathy Therapeutics Assessment
Major key companies are working proactively in the Leber’s Hereditary Optic Neuropathy Therapeutics market to develop novel therapies which will drive the Leber’s Hereditary Optic Neuropathy treatment markets in the upcoming years are GenSight, Stealth Biotherapeutics, and others.
Learn more about the emerging Leber’s Hereditary Optic Neuropathy therapies & key companies @ https://www.delveinsight.com/sample-request/lebers-hereditary-optic-neuropathy-lhon-market
Leber’s Hereditary Optic Neuropathy Report Key Insights
1. Leber’s Hereditary Optic Neuropathy Patient Population
2. Leber’s Hereditary Optic Neuropathy Market Size and Trends
3. Key Cross Competition in the Leber’s Hereditary Optic Neuropathy Market
4. Leber’s Hereditary Optic Neuropathy Market Dynamics (Key Drivers and Barriers)
5. Leber’s Hereditary Optic Neuropathy Market Opportunities
6. Leber’s Hereditary Optic Neuropathy Therapeutic Approaches
7. Leber’s Hereditary Optic Neuropathy Pipeline Analysis
8. Leber’s Hereditary Optic Neuropathy Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Leber’s Hereditary Optic Neuropathy Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Leber’s Hereditary Optic Neuropathy Competitive Intelligence Analysis
4. Leber’s Hereditary Optic Neuropathy Market Overview at a Glance
5. Leber’s Hereditary Optic Neuropathy Disease Background and Overview
6. Leber’s Hereditary Optic Neuropathy Patient Journey
7. Leber’s Hereditary Optic Neuropathy Epidemiology and Patient Population
8. Leber’s Hereditary Optic Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Leber’s Hereditary Optic Neuropathy Unmet Needs
10. Key Endpoints of Leber’s Hereditary Optic Neuropathy Treatment
11. Leber’s Hereditary Optic Neuropathy Marketed Products
12. Leber’s Hereditary Optic Neuropathy Emerging Therapies
13. Leber’s Hereditary Optic Neuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Leber’s Hereditary Optic Neuropathy Market Outlook (7 major markets)
16. Leber’s Hereditary Optic Neuropathy Access and Reimbursement Overview
17. KOL Views on the Leber’s Hereditary Optic Neuropathy Market
18. Leber’s Hereditary Optic Neuropathy Market Drivers
19. Leber’s Hereditary Optic Neuropathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting